Literature DB >> 915341

e antigen and antibody, DNA polymerase, and inhibitors of DNA polymerase in acute and chronic hepatitis.

R Cappel, F DeCuyper, D Van Beers.   

Abstract

A high positive correlation was found between e antigen (HBe Ag) and DNA polymerase in hemodialyzed patients with acute hepatitis B, chronic carriers of hepatitis B surface antigen undergoing hemodialysis, and patients with chronic hepatitis. In contrast, the correlation was poor in nonhemodialyzed patients with acute hepatitis. Among the patients with chronic hepatitis, HBe Ag and DNA polymerase were were found mostly in those with aggressive hepatitis and rarely in those with persistent hepatitis. This difference was significant (P less than 0.01) and suggests that the persistence of these antigens may be a factor in the progression of the disease. Our data also indicate that the development of antibodies to HBe Ag (anti-HBe) might be a sign of a favorable prognosis, since 50% of the patients with persistent hepatitis vs. 6% of the patients with aggressive hepatitis were anti-HBe-positive. Inhibitors of DNA polymerase, which are possibly antibodies, appeared regularly after acute hepatitis and were transient. Their presence may be associated with viral replication.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 915341     DOI: 10.1093/infdis/136.5.617

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  The significance of the HBeAg/anti-HBe system in hemodialysis patients. A multicenter study.

Authors:  F Fiaccadori; S David; G Faggion; N Feriani; C Ferrari; V Franco; T Giuberti; C Grutta D'Auria; G La Greca; G Magnani
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

Review 2.  The hepatitis B virus and its DNA polymerase: the prototype three-D virus.

Authors:  S Z Hirschman
Journal:  Mol Cell Biochem       Date:  1979-07-15       Impact factor: 3.396

3.  Characterization of 'e' antigen associated with hepatitis B.

Authors:  R S Tedder; F G Bull
Journal:  Clin Exp Immunol       Date:  1979-03       Impact factor: 4.330

4.  Failure to detect naturally occurring serum inhibitors of hepatitis B virus deoxyribonucleic acid polymerase.

Authors:  G Hess; G Arnold; H H Dormeyer; W Koesters; G Gahl; H G Hoffmann; H Schönborn; K H Meyer zum Büschenfelde
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

5.  Changes in hepatitis B virus DNA polymerase in relation to the outcome of acute hepatitis type B.

Authors:  A Alberti; S Diana; A L Eddleston; R Williams
Journal:  Gut       Date:  1979-03       Impact factor: 23.059

6.  The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.

Authors:  Qingqing Cai; Kailin Chen; Jie Chen; Shaoxu Wu; Qirong Geng; Huiqiang Huang; Tongyu Lin; Wenqi Jiang; Zhongjun Xia; Huaxin Duan; Huilan Rao; Mengfei Yao; Liyang Hu
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

7.  The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Xue-Yan Wang; Tim J Harrison
Journal:  J Hepatol       Date:  2008-11-14       Impact factor: 25.083

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.